» Articles » PMID: 19549886

MDA-MB-435 and M14 Cell Lines: Identical but Not M14 Melanoma?

Overview
Journal Cancer Res
Specialty Oncology
Date 2009 Jun 25
PMID 19549886
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

A controversy has arisen over the past several years about the true origin of the human MDA-MB-435 cell line. Originally described as a human breast cancer cell line, subsequent expression array studies instead suggested a gene expression profile consistent with a melanoma origin. Subsequent karyotype and comparative genomic hybridization studies supported the idea that current stocks of both MDA-MB-435 cells and M14 melanoma cells must be identical cell lines, and the conclusion was drawn that both cell lines were in fact M14 melanoma cells. However, an alternate conclusion based on these data is that both cell lines are indeed identical, but are in fact MDA-MB-435 breast cancer cells. There is evidence that many cell lines can display "lineage infidelity" and that assignment to tissue type is unreliably made based on expression patterns. Evidence from the literature is presented here that is inconsistent with both lines being of M14 melanoma origin, but rather is consistent with both cell lines being of MDA-MB-435 breast cancer origin.

Citing Articles

Osteopontin induces mitochondrial biogenesis in deadherent cancer cells.

Fnu G, Weber G Oncotarget. 2023; 14:957-969.

PMID: 38039408 PMC: 10691814. DOI: 10.18632/oncotarget.28540.


Synergistic inhibition of NUDT21 by secretory S100A11 and exosomal miR-487a-5p promotes melanoma oligo- to poly-metastatic progression.

Zeng B, Chen Y, Chen H, Zhao Q, Sun Z, Liu D Mol Oncol. 2023; 17(12):2743-2766.

PMID: 37356089 PMC: 10701767. DOI: 10.1002/1878-0261.13480.


Metastasis suppressor NME1 in exosomes or liposomes conveys motility and migration inhibition in breast cancer model systems.

Khan I, Gril B, Hoshino A, Yang H, Lee M, Difilippantonio S Clin Exp Metastasis. 2022; 39(5):815-831.

PMID: 35939247 PMC: 10642714. DOI: 10.1007/s10585-022-10182-7.


p32 promotes melanoma progression and metastasis by targeting EMT markers, Akt/PKB pathway, and tumor microenvironment.

Sinha S, Singh S, Jangde N, Ray R, Rai V Cell Death Dis. 2021; 12(11):1012.

PMID: 34711805 PMC: 8553772. DOI: 10.1038/s41419-021-04311-5.


Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer.

Bonitto E, McKeown B, Goralski K Pharmacol Res Perspect. 2021; 9(6):e00886.

PMID: 34708587 PMC: 8551564. DOI: 10.1002/prp2.886.